The company is a leading conglomerate with a diverse range of business operations across multiple industries. The website is structured to provide detailed financial information through sections like “Annual Report,” “Quarterly Report,” and “Price Sensitive Information,” which include links to various reports from recent years and updates on financial performance, such as notices about bond issuances. The company operates in several key sectors, including textiles, pharmaceuticals, personal protective equipment (PPE), ceramics, information and communication technology (ICT), real estate and trading, media, financial services, energy, and travel and tourism. As the largest entity within its group, the company plays a significant role in driving economic activities and growth across these industries, reflecting its strong market presence and commitment to diversified business interests.

Established in 2021, this GMP manufacturer is a leading CTD dossier owner and manufacturer, supplying high-quality pharmaceutical products across multiple countries and regions worldwide. Specializing in cytotoxic products, it operates advanced production lines for liquid injections, lyophilized injections, tablets, and capsules. As a CTD dossier owner and manufacturer, it adheres to strict regulatory standards, holding GMP approvals from WHO cGMP, ISO 9001:2015, and authorities in the Philippines, Cambodia, Kenya, Sri Lanka, and Syria. This GMP manufacturer, as a CTD dossier owner and manufacturer, ensures excellence in pharmaceutical development.

Established in 2003, this manufacturer specializes in developing, manufacturing, and marketing a diverse portfolio of pharmaceutical products. As a CTD dossier owner and manufacturer, it holds WHO-GMP certification and complies with various international regulatory standards, including EFDA Ethiopia, PPB Kenya, FDA Philippines, NAFDAC Nigeria, DPM Ivory Coast, MOH Cambodia, and NMHPRA Afghanistan. The manufacturer operates two state-of-the-art WHO-GMP manufacturing units producing general category formulations such as tablets, oral liquids, capsules, and sachets. A new facility under its sister concern, operational since May, is compliant with USFDA, PIC/S, and UKMHRA guidelines. As a CTD dossier owner and manufacturer, its products are distributed across multiple countries worldwide.